INTRODUCTION
Traumatic brain injury (TBI) can lead to chronic neurodegeneration and dementia in later life (1, 2) . Deposition of hyperphosphorylated protein tau neurofibrillary tangles is a pathological hallmark of this neurodegenerative process (3, 4) . Since the first observations in postmortem examinations of brain of boxers (5) , the pathological features and clinical correlations of tau neurofibrillary tangle deposition in chronic traumatic encephalopathy (CTE) after repetitive TBI have been increasingly well characterized (3, 6) . However, tau deposition also occurs after a single TBI, after which abundant and widely distributed neurofibrillary tangles have been found postmortem in about one-third of patients with TBI (7) . As in Alzheimer's disease (AD), all six isoforms of tau (including both 3-and 4-repeat isoforms) are observed in post-TBI tauopathy (3, 4) . However, the distribution of tau pathology after TBI follows a pattern distinct from that observed in AD, concentrating primarily in the depths of sulci and at points of geometric inflection in the cerebral neocortex, whereas the medial temporal lobe is relatively spared in early disease (7, 3) . Although the pathogenic role of TBI as a trigger for tau aggregation is not fully understood, traumatic axonal injury (TAI) appears to lead directly to tau hyperphosphorylation (8, 9) . Flortaucipir ([ (10, 11) . Flortaucipir demonstrated potent and specific nondisplaceable binding to tau neurofibrillary tangles in postmortem human brain tissue in AD (12) (13) (14) . Flortaucipir is relatively selective for tau, with no substantial binding to  amyloid (A), -synuclein, or TAR DNA binding protein in postmortem brain tissue (12) , although it also binds off-target to monoamine oxidases (15) as well as neuromelanin-and melanincontaining cells (12, 16) . In vivo, flortaucipir binding is increased in patients with AD with a regional pattern in keeping with the clinical phenotype (17) (18) (19) , cognitive profile (17, 18) , and estimated Braak and Braak staging (20) . In tau mutation carriers (MAPT gene) and in AD, the distribution of in vivo flortaucipir binding and that of postmortem tau pathology are strongly concordant (19, 21) . Furthermore, in both typical AD and posterior cortical atrophy, flortaucipir binding follows the pattern of regional atrophy as quantified by magnetic resonance imaging (MRI) (22, 23) .
A recent report on 26 former National Football League players (24) and a previous single case study (25) showed increased cerebral flortaucipir binding after exposure to repetitive TBI. However, the role of flortaucipir in quantifying tau pathology and its distribution in long-term survivors of a single TBI have not been studied. The relationships of tau pathology to clinical outcome and biomarkers of neurodegeneration are also unclear. Of particular interest is the relationship between tau pathology and white matter microstructural changes related to TAI, because these will help to clarify the pathophysiological relationship between the initial injury and progressive neurodegeneration.
Here, we used flortaucipir PET to study the distribution of tau pathology in individuals at least 18 years after a single moderate-severe TBI and in healthy controls. TBI participants were primarily recruited from a patient cohort under follow-up at the University of Glasgow, who have previously been followed up longitudinally in terms of cognitive and disability outcomes (26, 27) . We hypothesized that in 18 participants (86%), assault in 2 participants (10%), and fall from a height in 1 participant (5%). Glasgow Outcome Scale-Extended (GOS-E) median score was 6 (range, 4 to 8) at the time of assessment. In 15 TBI participants (71%), longitudinal clinical data were also available (27) , including GOS-E and Mini-Mental State Examination (MMSE) scores obtained at a median time point of 16 years (range, 9 to 19 years) after the injury and 17 years (range, 15 to 19 years) before the current clinical and imaging assessment. The demographic and clinical characteristics and apolipoprotein E (APOE) genotype of individual TBI participants are presented in Table 1 . Focal lesions were delineated on MRI as specified in the Supplementary Materials. Nineteen TBI participants (90%) had focal lesions apparent on MRI with a median volume of 1634 voxels (range, 12 to 23,118 voxels). A cerebellar lesion was present on structural MRI in one participant with TBI (P7). There were no cerebellar abnormalities on structural MRI in any other participants ( fig. S1 ).
Eleven healthy controls [five females and six males; median age, 57 years (range, 29 to 72 years)] of similar educational background and estimated premorbid intelligence to the TBI participants were also examined. Eight healthy control participants were recruited from the Institute of Health and Wellbeing, Head Injury Research Group, University of Glasgow, UK, and three healthy controls were recruited from the National Institute for Health Research (NIHR) Imperial Clinical Research Facility, London, UK. The demographic characteristics of the TBI and control groups are presented in Table 2 . We divided TBI participants into a good recovery and a disabled subgroup based on their GOS-E scores (disabled subgroup, GOS-E ≤ 6; good recovery subgroup, GOS-E > 6). Twelve participants [five females and seven males; median age, 48.5 years (range, 39 to 72 years)] with a median GOS-E of 5 (range, 4 to 6) were included in the disabled subgroup, and nine participants with TBI [two females and seven males; median age, 54 years (range, 29 to 65 years)] with a median GOS-E of 8 (range, 7 to 8) were included in the good recovery subgroup. Longitudinal clinical data were available for nine participants with TBI (75%) in the disabled group and six participants with TBI (67%) in the good recovery group. The demographic characteristics of these subgroups are presented in Table 2 . There was no significant difference in age or years of education when each of the subgroups was compared to healthy controls (disabled TBI versus healthy controls: age, independent t test t = −0.91, P = 0.37; education, Mann-Whitney-Wilcoxon W = 60, P = 0.73; good recovery TBI versus healthy controls: age, t = −0.93, P = 0.36; education, W = 64.5, P = 0.26). Estimated premorbid intelligence [Wechsler Test of Adult Reading (WTAR)] was lower in the disabled TBI subgroup when compared to healthy controls (W = 23, P = 0.009) but not significantly different between good recovery TBI and healthy controls (W = 53.5, P = 0.79). WTAR score did not correlate with age at injury in either the disabled TBI subgroup or the TBI group overall (Spearman  = −0.04, P = 0.89 and  = 0.18, P = 0.43, respectively).
Neuropsychological performance
When compared to healthy controls, participants with TBI manifested impairments on multiple cognitive domains including processing speed, executive function, motivation, inhibition, and verbal and visual memory (Table 2) , in a neuropsychological profile typical of TBI. On most neuropsychological measures, these differences were driven by the disabled TBI subgroup (fig. S2 ). The good recovery TBI subgroup had similar outcomes as healthy controls on most measures, with the exception of the Frontal Systems Behavior (FrSBe) executive and apathy scores, on which both good recovery and disabled TBI subgroups were impaired when compared to healthy controls (good recovery TBI: FrSBe-E, W = 74, P = 0.003; FrSBe-A, W = 63.5, P = 0.046; disabled TBI: FrSBe-E, W = 107.5, P < 0.001; FrSBe-A, W = 94, P = 0.005). The good recovery TBI subgroup performed better than the disabled subgroup on several cognitive domains including logical reasoning, processing speed, executive function, motivation, inhibition, verbal and visual memory, and mood assessment ( Table 2) .
As shown in Table 2 , there was evidence of cognitive decline on longitudinal assessment (average, −1.3 or −0.073 MMSE points per year) in the disabled TBI subgroup, whereas the good outcome TBI subgroup showed improvement of cognitive performance over time (average, 1 or 0.058 MMSE points per year), with longitudinal change being significantly different between the TBI subgroups (W = 7, P = 0.041; Table 2 ). Fig. 2 ). Axial images are displayed in radiological convention at MNI coordinate 55. Patchy cortical and subcortical increase in tracer uptake is observed in some TBI participants, most consistently in the lateral occipital cortex (P1 to P8 and P10), whereas others show similar BP ND values as controls (P17 to P21). The corresponding clinical characteristics are presented in Table 1 . Participant designations correspond to those in Table 1 , Fig. 2, and fig. S1 .
Flortaucipir binding in individual participants with TBI
To assess flortaucipir binding and its distribution in the brain in individual participants with TBI, voxel-wise z-scores of Montreal Neurological Institute (MNI)-registered flortaucipir nondisplaceable binding potential (BP ND ) images were derived for each patient versus the healthy control group. The resulting z-score maps describe the distribution of flortaucipir in individual participants with TBI relative to variations in binding seen in healthy participants. As illustrated in Fig. 1 , several participants with TBI had increased flortaucipir binding in a patchy cortical and subcortical distribution, involving both gray and white matter (Fig. 1, P1 to P8 and P10). In contrast, other participants with TBI had similar flortaucipir BP ND to that of healthy controls (Fig. 1, P17 to P22).
The number of voxels with high BP ND (z > 1.645; corresponding to one-tailed P < 0.05) was used to measure the spatial extent of increased flortaucipir signal in individual TBI participants (Fig. 2) . Participants with TBI had a median of 841 voxels above threshold (range, 0 to 15,809). For comparison, voxel-wise z-scores were also derived for each healthy control versus the rest of the control group. In controls, the median number of voxels above threshold was 4 (range, 0 to 253; Fig. 2 ).
Eight participants with TBI (38%) had >2000 voxels (equivalent to 16 cm 3 of brain volume) above threshold, indicating spatially extensive flortaucipir signal increase, whereas further seven participants (33%) showed increased signal of more spatially limited extent (254 to 1999 voxels; Fig. 2 ). The remaining six participants (29%) had less than 253 voxels above threshold, falling within the range of the healthy control group. There was no difference in flortaucipir spatial extent when comparing between disabled and good functional outcome subgroups (Mann-Whitney-Wilcoxon W = 68.5, P = 0.32).
Reduced flortaucipir binding within focal lesions in TBI
Flortaucipir binding within focal lesions was significantly reduced when compared to nonlesioned cerebral areas (Wilcoxon signed-rank V = 22, P = 0.002; fig. S3 ). Areas of markedly reduced flortaucipir uptake (in black) in Fig. 1 correspond to focal lesions in individual TBI participants (cf. fig. S1 ). Focal lesion size (number of voxels) did not correlate with average flortaucipir BP ND within the nonlesioned gray or white matter (Spearman  = −0.37, P = 0.10 and  = −0.15, P = 0.51, respectively; fig. S3 ) or with flortaucipir spatial extent (number of voxels above threshold;  = −0.06, P = 0.78; fig. S3 ).
Increased flortaucipir binding in the TBI patient group versus healthy controls Flortaucipir BP ND was next compared between TBI and healthy control groups, in a nonparametric voxel-wise analysis, excluding lesioned areas ( fig. S1 ) and the striatum where off-target binding is observed with this tracer. Flortaucipir binding was significantly higher in TBI participants than in healthy controls in the right lateral occipital cortex (P < 0.05, adjusted for multiple comparisons; Fig. 3, inset) . When each of the TBI subgroups was independently compared to healthy controls, significantly increased flortaucipir binding was found in both TBI subgroups, in the same right lateral occipital area (P < 0.05, adjusted for multiple comparisons; fig. S4 and cf. Fig. 3 ). There was no significant difference in flortaucipir binding when comparing between the disabled (GOS-E ≤ 6) and good outcome (GOS-E > 6) TBI subgroups ( fig. S4 ). There were no areas of significantly decreased binding in the TBI group or subgroups compared to healthy controls (all P > 0.05; fig. S4 ).
In addition, we examined flortaucipir BP ND within a medial temporal lobe region of interest (ROI) including the entorhinal, perirhinal, and parahippocampal cortices and the hippocampus, a region typically affected by tau accumulation in AD. There was no significant difference in flortaucipir binding within this ROI between the TBI group, or either of the disabled or good recovery TBI subgroups, and healthy controls (all TBI versus healthy controls: Mann-Whitney-Wilcoxon W = 108, P = 0.78; disabled TBI versus healthy controls: W = 57, P = 0.61; good recovery TBI versus healthy controls: W = 51, P = 0.94; fig. S5 ).
Correlations between flortaucipir and CSF total tau, phosphorylated tau, and ubiquitin C-terminal hydrolase L1 in TBI Next, CSF and plasma biomarkers of neurodegeneration and neuronal damage, including total tau (T-tau), tau phosphorylated at amino acid 181 (P-tau), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), A42, neurofilament light (NFL), glial fibrillary acidic protein (GFAP), and protein S100 were assessed in TBI and healthy controls, and their relationship with flortaucipir binding was explored. CSF data were available from 19 participants with TBI and 10 healthy controls.
In TBI, CSF T-tau was significantly correlated with flortaucipir BP ND in the cerebral cortical gray matter (Spearman  = 0.53, P = 0.022; S6 ). There were no differences in T-tau or P-tau concentration in CSF or plasma between TBI and healthy control groups (CSF T-tau: W = 93, P = 0.95; CSF P-tau: W = 67, P = 0.21; plasma T-tau: W = 118, P = 0.76; fig. S6 ). UCH-L1 in the CSF in TBI participants also positively correlated with flortaucipir BP ND in the gray matter (Spearman  = 0.52, P = 0.023; Fig. 4C ) but not in the white matter ( = 0.42, P = 0.073; fig. S7 ). There was no association between plasma UCH-L1 and flortaucipir binding in TBI ( fig. S7 ). In healthy controls, there were no associations between flortaucipir binding and UCH-L1 in the CSF or plasma ( fig. S7 ). There was no difference between TBI and control groups in UCH-L1 concentration ( fig. S7 ). There were also no associations between flortaucipir BP ND and A42, NFL, GFAP, or S100 in TBI or healthy controls and no difference between TBI and control groups in the CSF or plasma ( fig. S7 ).
Flortaucipir spatial extent and white matter damage in TBI Next, we investigated the relationship between flortaucipir binding and structural brain injury produced by TBI (28) . White matter integrity measured by fractional anisotropy (FA) was significantly reduced in TBI when compared to healthy controls (Mann-Whitney-Wilcoxon W = 44, P = 0.004; Fig. 5A ), in keeping with the presence of TAI in TBI. As expected in TBI (29) , reduced FA correlated with worse performance on multiple cognitive measures (table S1). Tissue density measured by VBM was also significantly reduced in the nonlesioned white matter in TBI (W = 61, P = 0.031; Fig. 5B ). Tissue density in the nonlesioned gray matter was not significantly different between TBI and healthy control groups (W = 113, P = 0.94; Fig. 5C ).
The spatial extent of flortaucipir binding (number of voxels with BP ND z > 1.645) correlated with the degree of white matter damage seen in TBI participants. The number of voxels showing increased flortaucipir binding was negatively correlated with both average FA (Spearman  = −0.48, P = 0.027; Fig. 5D ) and average white matter density ( = −0.46, P = 0.037; Fig. 5E ), in keeping with a relationship between cerebral tau pathology with microstructural white matter disruption. There was no significant correlation between flortaucipir spatial extent and gray matter tissue density ( = −0.31, P = 0.17; Fig. 5F ). fig. S8 ). There was considerable between-subject variability in these effects (Fig. 6, B and D, and  fig. S8B ).
Cortical flortaucipir binding and white matter microstructural damage Next, we examined whether flortaucipir BP ND within the right lateral occipital cortical area where flortaucipir signal was increased in TBI versus controls (Fig. 3) was associated with white matter tract FA. Increased right lateral occipital flortaucipir binding was associated with reduced FA in remote white matter regions, including association, commissural, and projection tracts (Fig. 7, A and B, and table S2 ). Correlations were observed in the genu and body of the corpus callosum, as well as in several association tracts within the ipsilateral (right) hemisphere, including the cingulum bundle, inferior longitudinal fasciculus, uncinate fasciculus, and anterior thalamic radiation (Fig. 7B  and table S2 ), but not in the contralateral hemisphere ( fig. S9 and  table S2 ). Higher cortical flortaucipir BP ND was associated with reduced tissue density in remote white matter regions including the corpus callosum and right prefrontal white matter (Fig. 7C) . The same analysis for gray matter density did not show an association between flortaucipir BP ND within the lateral occipital cluster and cerebral cortical gray matter density (P > 0.05, corrected for multiple comparisons).
Flortaucipir binding and clinical measures in TBI
There were no correlations of average flortaucipir BP ND in the cerebral gray or white matter or the spatial extent of high flortaucipir signal in TBI participants (number of voxels above BP ND z > 1.645) with age, time since injury, disability (GOS-E), or any neuropsychological measures in the TBI participants (all P > 0.05, false discovery rate (FDR)-adjusted; table S3).
APOE 4 genotype interactions with flortaucipir binding and time since injury, CSF A42, white matter density, and MMSE scores in TBI There were no overall differences between participants with at least one APOE 4 allele and those without an APOE 4 allele in either cerebral flortaucipir BP ND or in flortaucipir spatial extent in the TBI group (Mann-Whitney-Wilcoxon W = 41, P = 0.46 and W = 44, P = 0.60, respectively; fig. S10 ). In further exploratory analyses, we examined whether APOE carrier status (presence of at least one 4 allele) influenced the relationship between flortaucipir measures (average cerebral BP ND and spatial extent) and age, time since injury, CSF biomarkers, white matter MRI measures, and neuropsychological performance in TBI. Interactions between APOE status and each of the above variables on flortaucipir measures were examined using linear regression in the TBI group. Interaction plots are shown in fig. S11 .
There was an interaction between APOE genotype and time since injury on cerebral flortaucipir BP ND (F 1,17 = 15.11, P = 0.001) but not on flortaucipir spatial extent. Flortaucipir BP ND increased with time elapsed since the TBI in APOE 4 carriers but not in 4 noncarriers ( fig. S11 ). Age did not interact with APOE genotype on average cerebral flortaucipir BP ND or on flortaucipir spatial extent ( fig. S11 ).
There was an interaction between APOE genotype and CSF A42 on flortaucipir BP ND (F 1,15 = 6.15, P = 0.026) but not on flortaucipir spatial extent in TBI ( fig. S11 ). Higher cerebral flortaucipir binding was associated with lower A42 concentration in CSF in APOE 4 carriers but not in 4 noncarriers ( fig. S11 ). There were no interactions on flortaucipir measures between APOE 4 carrier status and T-tau, P-tau, UCH-L1, NFL, GFAP, or S100 CSF concentrations ( fig. S11 ).
The effect of white matter tissue density (derived from VBM) on flortaucipir spatial extent was influenced by APOE genotype (F 1,17 = 6.90, P = 0.018), with 4 noncarriers showing increased flortaucipir binding with reducing white matter tissue density, which was not observed in APOE 4 carriers ( fig. S11 ). There were no interactions between white matter tissue density and APOE genotype on average cerebral flortaucipir BP ND and no interactions between gray matter tissue density or FA and APOE genotype on flortaucipir measures (fig. S11) .
APOE genotype influenced the relationship of longitudinal MMSE scores and flortaucipir binding, with decreasing MMSE scores over time associated with higher cerebral flortaucipir BP ND in 4 noncarriers but not in 4 carriers (F 1,10 = 40.76, P < 0.0001; fig. S11 ). Current MMSE scores also interacted with APOE 4 carrier status on flortaucipir spatial extent, with current MMSE scores being lower with increasing spatial extent in 4 noncarriers but not in 4 carriers (F 1,17 = 6.14, P = 0.024; fig. S11 ).
Similar off-target binding in TBI and healthy controls
In keeping with the known off-target binding of flortaucipir to neuromelanin (12), flortaucipir BP ND was increased in the striatum both in TBI participants and in healthy controls when compared to the rest of the cerebral white and gray matter, excluding focal lesions (TBI: Wilcoxon signed-rank V = 214, P = 0.0002; controls: V = 66, P = 0.001; fig. S12 ). However, flortaucipir BP ND in the striatum and in the choroid plexus (16) was not different between TBI participants and healthy controls ( fig. S12 ).
DISCUSSION
Hyperphosphorylated tau deposition is a key pathological feature of neurodegeneration triggered by TBI (3, 4) . Patients are at increased risk of AD and CTE after TBI, both characterized by the accumulation of tau pathology (1, 30, 31) . PET ligands have recently been developed that specifically bind hyperphosphorylated tau, enabling the detection of tau pathology in vivo (32) . We used flortaucipir PET to investigate tau pathology in a well-characterized cohort of individuals who were examined many years after a single moderate-severe TBI (26, 27) . As predicted, there was considerable variability in the extent of flortaucipir binding across TBI participants. Broadly, a third of TBI participants showed extensive increases in cerebral flortaucipir binding, a third showed more limited increases, and a third showed no abnormality. The proportion of individuals with increased flortaucipir binding is much higher than would be expected in the general population in this age group (33) . At the group level, TBI participants showed elevated flortaucipir binding when compared to age-and educationmatched healthy controls.
Flortaucipir binds to neurofibrillary tangles containing abnormal tau in postmortem human brain tissue in AD (12) (13) (14) . A lack of specificity has been a critical issue with previous PET tau ligands (34) , but flortaucipir is more selective and does not show substantial A, -synuclein, or TDP-43 binding in postmortem brain tissue (12) . However, off-target binding to monoamine oxidases and neuromelaninand melanin-containing cells is a known limitation (12, 15, 16) . (17-19), cognitive profile (17, 18) , and estimated Braak and Braak staging (20) . Tau pathology seen after TBI appears to be similar to AD, with all six isoforms of tau (including both 3-and 4-repeat isoforms) observed (3, 4) . As a result, flortaucipir is expected to bind tau pathology seen after TBI in a similar way to AD, albeit with a distinct spatial pattern (3). The pattern of flortaucipir binding potentially provides diagnostic information about the type of posttraumatic neurodegeneration. Tau pathology seen after TBI often has a distribution distinct from AD. In cases of CTE, tau pathology is concentrated in depths of cortical sulci (3, 6) and can be widely distributed in cortical areas after single TBI (7). In our study, some patients showed extensive flortaucipir binding in cortical areas and in parts of the white matter. This spatial pattern would be atypical for AD (35) but is more in keeping with CTE (3, 4) . It is also compatible with the spatially extensive tau neurofibrillary tangle pathology seen in about one-third of patients with chronic TBI (7) .
The relationship between tau pathology and flortaucipir binding is supported by our CSF results. CSF tau is raised in incipient AD (36) and other tauopathies (37) and provides a diagnostic biomarker for AD (38) . CSF tau increases in the days after TBI, generally falling to normal concentration 8 to 12 weeks after the injury (39, 40) . To our knowledge, our study is the first to examine CSF tau several years after moderate-severe TBI. CSF T-tau and P-tau were not increased across the TBI group, which might be due to the high variability within the TBI group. CSF T-tau and P-tau concentrations correlated positively with flortaucipir binding in the cerebral cortex and white matter, respectively, supporting the conclusion that increased flortaucipir binding is indicative of the presence of tau pathology. We also observed a positive correlation between CSF UCH-L1 concentration and cortical flortaucipir uptake. In the acute phase, UCH-L1 may indicate the presence of neuronal injury after TBI (41) . It is abundant in cerebral neurons and is an important component of the ubiquitin-proteasome system, (42) . Dysfunction of UCH-L1 is implicated in a number of neurodegenerative diseases (43, 44) , and UCH-L1 is found within misfolded protein aggregates, including neurofibrillary tangles (45) . CSF UCH-L1 is elevated in patients with AD (46), and our results suggest that the link between TBI and dysfunction in the ubiquitin-proteasome system warrants further investigation.
We also showed a relationship between flortaucipir binding and TAI. This is in keeping with a causative role for TAI in the pathophysiology of posttraumatic tau pathology. Mechanical forces exerted at the time of head injury are thought to disrupt axonal organization, producing damage to microtubule structure and associated axonal tau (4) . This damage may lead to hyperphosphorylation of tau, misfolding, and neurofibrillary tangle formation, which eventually causes neurodegeneration (8, 9, 47) . Mechanical forces are maximal in points of geometric inflection such as the base of cortical sulci (48) , where tau pathology is seen in CTE. In AD, increased flortaucipir binding is greater in cortical regions that show atrophy (22, 23) . We observed a different relationship after TBI. Flortaucipir binding was increased in white matter areas that also showed reduced FA and atrophy. This suggests that tau pathology was more marked in areas of TAI. In addition, cortical flortaucipir binding also correlated with the extent of TAI within the white matter. For example, flortaucipir binding in the right lateral occipital cortex, the most consistent area of increase, was correlated with reduced FA in a tract directly connected to that cortical area, the inferior longitudinal fasciculus. This relationship might be explained by slow Wallerian degeneration that follows the initial injury and leads to the accumulation of tau pathology in connected cortical regions (49) . Alternatively, prion-like spread of tau pathology might over time result in the cortical accumulation of tau pathology in regions that are connected to white matter regions initially damaged by TAI (50, 51) . We have previously reported a similar relationship between cortical amyloid pathology measured using [ 11 C]-PiB PET and the degree of TAI in connected tracts (52) , suggesting that structural connectivity may influence the neuroanatomical distribution of posttraumatic tau and amyloid pathology in similar ways.
A recent study on former National Football League players, exposed to repetitive TBI and manifesting cognitive, mood, and behavioral symptoms, also found raised cerebral flortaucipir binding, which increased with years of exposure to repetitive TBI (24) . With our results, this supports the hypothesis that the risk for neurodegeneration from TBI may be dose dependent (1), produced either by a single severe TBI or repeated exposure to more minor TBI.
Genetic factors may partially explain the variability in the neurodegenerative trajectory after TBI (53, 54) . APOE 4, the strongest risk factor for sporadic AD, is associated with increased A and tau pathology (55) , and it is also the strongest genetic predictor of adverse outcome after TBI (56) . APOE 4 may act synergistically with TBI to elevate the risk of neurodegeneration (30, 57) . Therefore, in exploratory analyses, we examined how APOE 4 carrier status might influence flortaucipir binding. Flortaucipir binding increased with time since TBI in APOE 4 carriers and was associated with lower A42 concentrations in the CSF (indicating higher A42 concentrations in the brain) in 4 carriers. This supports an influence of APOE 4 on the risk of neurodegeneration after TBI. In keeping with these findings, A plaque pathology after TBI is more prevalent in individuals with at least one APOE 4 allele (57) . Results from animal models also support the association between APOE 4 genotype and A pathology after TBI (58) .
Our study has a number of limitations. The relatively small sample size may have limited our ability to detect associations between flortaucipir binding and clinical outcomes. Hence, the absence of a clinical effect should be interpreted with caution, because our study is unlikely to have been adequately powered for these outcomes. In AD, flortaucipir uptake was associated with poorer performance in various cognitive domains in regionally specific patterns (17) . However, the situation is likely to be more complex after TBI because the influence of the initial injury on cognitive state will confound progressive neurodegenerative effects, resulting in the need for larger sample sizes. Estimated premorbid intelligence was lower in the disabled TBI subgroup when compared to healthy controls. However, vocabulary development may be adversely affected by TBI during development (59). Hence, it is possible that performance on WTAR was directly reduced by the TBI, especially in individuals injured during childhood. Flortaucipir binds off-target to monoamine oxidases and neuromelanin, which is particularly apparent in the striatum and choroid plexus (12, 13, 15, 16) . This off-target flortaucipir binding may have limited our ability to detect underlying tau pathology in these regions. In addition, a contribution from non-tau pathology cannot be excluded with certainty. Flortaucipir binding increases have been reported in semantic variant primary progressive aphasia, where the underlying pathology is TDP-43 (60), although flortaucipir binding to TDP-43 has not been demonstrated postmortem (12) . Off-target binding has also been reported in areas of acute parenchymal and subarachnoid hemorrhage but not in areas showing superficial siderosis due to chronic hemorrhage (12) . This is unlikely to be a major confound in our study because there were no acute hemorrhagic lesions in our participants and binding was reduced within focal lesions. Flortaucipir signal is reduced at the site of focal lesions. Therefore, the presence of a focal lesion in one or more TBI participants within a given brain area would be expected to reduce our sensitivity in detecting flortaucipir group effects within that area. To minimize the impact of lesions in our analysis, we took into account the location of focal lesions as regressors in voxel-wise group comparisons. Last, brain atrophy can affect on PET results, but we used stringent measures to minimize the effects of atrophy during preprocessing. Moreover, the relationship between increased flortaucipir binding and reduced white matter tissue density is unlikely to be artifactual, because nonspecific flortaucipir binding is expected to be reduced within areas of reduced tissue density.
In summary, we show that flortaucipir binding is increased many years after a single moderate-severe TBI. Increased binding was associated with CSF indicators of neurodegeneration, including T-tau and P-tau, as well as the presence of TAI that may provide the initial trigger to its accumulation. The ability to detect tau pathology in vivo after TBI has major potential implications for diagnosis and prognostication of clinical outcomes after TBI. It is also likely to assist in patient selection and stratification for future treatment trials targeting tau. 
MATERIALS AND METHODS

Study design
This study was designed to assess whether flortaucipir PET provides evidence of tau pathology in individuals several years after a single moderate-severe TBI when compared to healthy controls. We also examined the relationship of flortaucipir signal with CSF and blood biomarkers, MRI measures of axonal injury, and cognitive and disability outcomes. Imaging assessment and biological sampling were cross sectional, and longitudinal cognitive and disability measures were available in a subset of individuals with TBI. The sample size was calculated to provide 80% statistical power with a type 1 error rate of 0.05 to detect an increase in flortaucipir binding in TBI compared to controls, based on effect sizes extrapolated from previous flortaucipir data on AD (11) and from postmortem data showing tau pathology in about a third of individuals after moderate-severe TBI (7). Investigators performing the PET modeling, MRI processing, and lesion delineation were blinded as to clinical outcomes and biomarker data. Randomization was not applicable in this observational study.
TBI participants were primarily recruited from two TBI cohorts under follow-up at the Institute of Health and Wellbeing, Head Injury Research Group, University of Glasgow, UK. The original cohorts included all individuals acutely admitted with TBI to the Southern General Hospital, Glasgow between 1968 and 1985 (27) and between 1996 and 1999 (26) . These individuals have been followed up longitudinally in terms of cognitive, well-being, and disability outcomes (26, 27) . Members of these follow-up cohorts fulfilling the inclusion criteria for the current study were invited to participate with the assent of their general practitioner (primary care physician). Additional TBI participants fulfilling the inclusion criteria were recruited from the specialist multidisciplinary TBI clinic at Imperial College Healthcare NHS Trust, London, UK. Individuals were recruited into the TBI group with the following inclusion criteria: (i) a history of a single moderate-severe TBI [according to Mayo classification (61)], (ii) age over 18 years, (iii) capacity to provide written informed consent, (iv) no prior neurological or psychiatric illness, (v) no contraindication to PET or prior radiation exposure that, when combined with the dose from the present study, would exceed 10 mSv in addition to the natural background radiation in the previous 3 years, (vi) no contraindication to MRI, and (vii) no medication use or allergies that may compromise participant safety or interfere with study procedures. TBI participants were divided into two subgroups based on functional outcome. Poor functional outcome was defined as a GOS-E score of 6 or less (moderatesevere disability) at the time of assessment and those with GOS-E greater than 6 as good outcome. Healthy volunteers of similar age and socioeconomic background as the TBI participants were also recruited. The study was approved by the Westminster Research Ethics Committee and the Administration of Radioactive Substances Advisory Committee. All participants gave written informed consent.
Procedures
All participants were administered an intravenous bolus of flortaucipir (also known as [ F]T807; average dose, 250 megabecquerels), and dynamic PET scans were acquired over 90 min. Flortaucipir was supplied by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, and PET image acquisition was carried out at Imanova Centre for Imaging Sciences (currently Invicro London). Flortaucipir PET data were analyzed with the Molecular Imaging and Kinetic Analysis Toolbox (www.miakat.org) using the simplified reference tissue model (62, 63) with cerebellar gray matter as the reference tissue, based on postmortem studies in CTE that demonstrated relative sparing from tau pathology in that region (3, 64) . All participants also underwent structural 3-T MRI, including volumetric T1 and diffusion tensor imaging (DTI). Details on PET and MRI acquisition and analyses are provided in the Supplementary Materials.
TBI and control participants took part in neuropsychological assessment and had venous blood and CSF sampling. Clinical assessment and blood and CSF sample acquisition were carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility. Details on neuropsychological assessments and biological sample analyses are provided in the Supplementary Materials.
Statistical analyses
Statistical analyses were carried out using R statistical software (www. r-project.org) (65), unless specified otherwise. Voxel-wise differences in BP ND between TBI participants and healthy controls, between each of the disabled TBI and good recovery TBI subgroups and healthy controls, and between these subgroups were assessed using permutation tests in the FMRIB Software Library (FSL) (66) . The same procedure was used to assess voxel-wise differences between TBI participants and healthy controls in (i) VBM-derived white matter density, (ii) gray matter density, and (iii) diffusion MRI-derived skeletonized FA. Voxels corresponding to structural lesions were excluded from the analyses using participants' lesion maps as individual voxel-wise repressors. All cerebral gray and white matter voxels were included except those corresponding to the striatum, where there is known off-target binding (12) . One thousand permutations were used, and results were cluster-corrected for multiple comparisons using threshold-free cluster enhancement (TFCE) and a family-wise error rate of 0.05. Localization of voxel clusters was reported on the basis of the Harvard-Oxford probabilistic atlas (67) and the Johns Hopkins University (JHU) DTI-based white matter atlas (68) .
To investigate whether white matter tau pathology shared common localization with TAI and/or white matter atrophy in TBI, we compared skeletonized FA and, separately, average white matter density (z-scores) within areas of high flortaucipir signal (BP ND z > 1.645) versus white matter areas where binding was not increased (BP ND z < 1.645) using (paired) Wilcoxon signed-rank tests. Any voxels corresponding to focal lesions were excluded. Only TBI participants with 15 or more white matter voxels with increased flortaucipir binding within the regions of interest were included.
To examine the localization of white matter microstructural damage predicted by increased flortaucipir cortical signal in TBI participants, standardized BP ND within the right parietal cortical area of flortaucipir increase in TBI was used as a regressor in a voxel-wise general linear model (GLM) of skeletonized FA and, separately, in a voxel-wise GLM of white matter density. Statistical significance was tested using permutation tests in FSL (66) . As previously, voxels corresponding to lesions were excluded for each individual, 1000 permutations were used and results were obtained using TFCE, corrected for multiple comparisons using a family-wise error rate of 0.05. Localization of voxel clusters was reported on the basis of the JHU DTI-based white matter atlas (68) . Post hoc correlations were examined using Spearman's rank correlation between standardized BP ND within the right parietal cortical area of flortaucipir increase in TBI participants and skeletonized FA in the following tracts: right and left superior longitudinal, inferior longitudinal, inferior fronto-occipital fasciculi and cingulum bundles, corpus callosum (genu, body, and splenium), as well as in the right and left corticospinal tracts as a control.
Correlations between clinical/neuropsychological measures and PET markers in TBI participants were examined using Spearman's rank correlation with FDR correction for multiple comparisons. Interactions between APOE genotype (presence of at least one 4 allele) and age, time since injury, CSF biomarkers, white matter MRI measures, and neuropsychological performance on cerebral flortaucipir BP ND and flortaucipir spatial extent were examined in the TBI group using linear regression in each case to assess the statistical significance of the interaction term and interaction plots to determine the direction of the effect in 4 carriers versus noncarriers. Assumptions of multiple linear regression analysis were tested as follows: Analysis of standard residuals was carried out to identify outliers; variance inflation factor was used to test for multicollinearity; Durbin-Watson test was conducted to test for independence of errors; and approximate normal distribution of errors, homoscedasticity, and linearity were assessed by plotting regression-standardized residuals.
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